107 related articles for article (PubMed ID: 7767254)
1. Prognostic factors in advanced Hodgkin's disease: problems and pitfalls. Towards an international prognostic index.
Gisselbrecht C; Ferme C
Leuk Lymphoma; 1995; 15 Suppl 1():23-4. PubMed ID: 7767254
[No Abstract] [Full Text] [Related]
2. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in Hodgkin's disease: problems and pitfalls.
Phillips G
Leuk Lymphoma; 1995; 15 Suppl 1():43-5. PubMed ID: 7767260
[No Abstract] [Full Text] [Related]
4. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
5. CHLVPP therapy for Hodgkin's disease identification of prognostic factors.
Vose JM
Leuk Lymphoma; 1995; 15 Suppl 1():13-4. PubMed ID: 7767251
[No Abstract] [Full Text] [Related]
6. BEACOPPescalated versus ABVD in advanced Hodgkin's lymphoma.
André M; Bosly A
Lancet Oncol; 2013 Sep; 14(10):911-2. PubMed ID: 23948347
[No Abstract] [Full Text] [Related]
7. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
[TBL] [Abstract][Full Text] [Related]
8. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy.
Marcus KC; Kalish LA; Coleman CN; Shulman LN; Rosenthal DS; Canellos GP; Mauch PM
J Clin Oncol; 1994 Dec; 12(12):2567-72. PubMed ID: 7989930
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin's lymphoma in the elderly: the results of 10 years of follow-up.
Feltl D; Vítek P; Zámecník J
Leuk Lymphoma; 2006 Aug; 47(8):1518-22. PubMed ID: 16966262
[TBL] [Abstract][Full Text] [Related]
10. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY.
Avalos BR; Klein JL; Kapoor N; Tutschka PJ; Klein JP; Copelan EA
Bone Marrow Transplant; 1993 Aug; 12(2):133-8. PubMed ID: 8401359
[TBL] [Abstract][Full Text] [Related]
11. [New prognostic factors in the treatment of patients with stage-III Hodgkin's disease].
Girshovich MM; Kanaev SV; Pozharisskiĭ KM; Golovanov SG; Barbashov AI
Vopr Onkol; 2010; 56(4):424-9. PubMed ID: 20968021
[TBL] [Abstract][Full Text] [Related]
12. Lymphocyte-predominant Hodgkin's disease: how little therapy is enough?
Aster JC
J Clin Oncol; 1999 Mar; 17(3):744-6. PubMed ID: 10071261
[No Abstract] [Full Text] [Related]
13. High-risk Hodgkin's disease prognostic factors.
Straus DJ
Leuk Lymphoma; 1995; 15 Suppl 1():41-2. PubMed ID: 7767259
[No Abstract] [Full Text] [Related]
14. [Long-term follow-up of Hodgkin's disease and unfavorable type of non-Hodgkin's lymphoma].
Sampi K; Maseki N; Sakurai M; Hattori M
Rinsho Ketsueki; 1988 Feb; 29(2):144-8. PubMed ID: 3385941
[No Abstract] [Full Text] [Related]
15. Autologous bone marrow transplantation in Hodgkin's disease.
Gisselbrecht C; Brice P; Lepage E; Brichon P; Gerota J; Boiron M
Nouv Rev Fr Hematol (1978); 1990; 32(1):5-7. PubMed ID: 2190180
[TBL] [Abstract][Full Text] [Related]
16. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
Andrieu JM; Colonna P
J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
[No Abstract] [Full Text] [Related]
17. [Hodgkin disease: should high-risk patients be selected and chemotherapy be intensified?].
Carde P
Bull Cancer; 1995 Aug; 82(8):637-49. PubMed ID: 7492820
[TBL] [Abstract][Full Text] [Related]
18. Combined chemotherapy and radiotherapy for Hodgkin's disease.
Prosnitz LR; Roberts KB
Oncology (Williston Park); 1992 Mar; 6(3):113-28; discussion 131-2, 137. PubMed ID: 1533138
[TBL] [Abstract][Full Text] [Related]
19. Greater curability in advanced Hodgkin's disease?
Portlock CS
Cancer J Sci Am; 1999; 5(5):264-5. PubMed ID: 10526665
[No Abstract] [Full Text] [Related]
20. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.
André M; Henry-Amar M; Pico JL; Brice P; Blaise D; Kuentz M; Coiffier B; Colombat P; Cahn JY; Attal M; Fleury J; Milpied N; Nedellec G; Biron P; Tilly H; Jouet JP; Gisselbrecht C
J Clin Oncol; 1999 Jan; 17(1):222-9. PubMed ID: 10458237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
